D-0385-2024 Class II Terminated

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0385-2024 was initiated by Eugia US LLC on Feb 22, 2024 and is designated Class II. Reason for recall: Failed Stability Specification: Water determination was found not complying with specification. The recall status is terminated (terminated Dec 22, 2025). Affected quantity: 1160 VIALS.

Recall details

Product Type
Drugs
Report Date
Mar 20, 2024
Initiation Date
Feb 22, 2024
Termination Date
Dec 22, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1160 VIALS

Product description

Tobramycin for Injection, USP, 1.2 grams per Pharmacy Bulk Package, Rx Only, For Intravenous Use, PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520, Carton NDC 55150-470-06, Vial NDC 55150-470-01.

Reason for recall

Failed Stability Specification: Water determination was found not complying with specification.

Distribution pattern

Nationwide

Code information

Lot #s: 3TB23001, 3TB23002, Exp. 04/30/2025.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0385-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0385-2024. Report a data issue: hello@regdatalab.com.